4591 Stock Overview
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Ribomic Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥91.00 |
52 Week High | JP¥199.00 |
52 Week Low | JP¥88.00 |
Beta | 0.55 |
1 Month Change | -7.14% |
3 Month Change | -13.33% |
1 Year Change | -50.27% |
3 Year Change | -75.00% |
5 Year Change | -85.58% |
Change since IPO | -95.22% |
Recent News & Updates
Recent updates
Shareholder Returns
4591 | JP Biotechs | JP Market | |
---|---|---|---|
7D | -1.1% | -2.0% | 1.0% |
1Y | -50.3% | -23.2% | 38.6% |
Return vs Industry: 4591 underperformed the JP Biotechs industry which returned -23.2% over the past year.
Return vs Market: 4591 underperformed the JP Market which returned 38.6% over the past year.
Price Volatility
4591 volatility | |
---|---|
4591 Average Weekly Movement | 6.5% |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 3.9% |
10% most volatile stocks in JP Market | 8.3% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4591's share price has been volatile over the past 3 months.
Volatility Over Time: 4591's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 25 | Yoshikazu Nakamura | https://www.ribomic.com |
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Ribomic Inc. Fundamentals Summary
4591 fundamental statistics | |
---|---|
Market cap | JP¥3.25b |
Earnings (TTM) | -JP¥979.00m |
Revenue (TTM) | JP¥62.00m |
52.4x
P/S Ratio-3.3x
P/E RatioIs 4591 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4591 income statement (TTM) | |
---|---|
Revenue | JP¥62.00m |
Cost of Revenue | JP¥0 |
Gross Profit | JP¥62.00m |
Other Expenses | JP¥1.04b |
Earnings | -JP¥979.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | -27.44 |
Gross Margin | 100.00% |
Net Profit Margin | -1,579.03% |
Debt/Equity Ratio | 0% |
How did 4591 perform over the long term?
See historical performance and comparison